Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749388 | 0.92 | PRCP (0.54) | PRCPALDH1A1MAPTEPHX2CYP2C9 | |
| SCHEMBL14736554 | 0.87 | PRCP (0.51) | PRCPALDH1A1LMNAMAPTEPHX2 | |
| SCHEMBL14749412 | 0.87 | PRCP (0.50) | PRCPKDM4EALDH1A1MAPTCYP2C9 | |
| SCHEMBL14749414 | 0.86 | PRCP (0.51) | PRCPKDM4EALDH1A1MAPTEPHX2 | |
| SCHEMBL12184132 | 0.85 | PRCP (0.51) | PRCPALDH1A1EPHX2CYP2C9KMT2A | |
| SCHEMBL14749396 | 0.85 | PRCP (0.51) | PRCPALDH1A1EPHX2CYP2C9KMT2A | |
| SCHEMBL14749383 | 0.83 | PRCP (0.49) | PRCPEPHX2CYP2C9CYP2J2 | |
| SCHEMBL14736875 | 0.82 | PRCP (0.59) | PRCPKDM4ECYP2C9KMT2A | |
| SCHEMBL14749417 | 0.82 | PRCP (0.51) | PRCPALDH1A1LMNACYP2C9KMT2A | |
| SCHEMBL14749283 | 0.82 | PRCP (0.49) | PRCPALDH1A1MAPTEPHX2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885KDM4E 576/4885ALDH1A1 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.